100114-57-6

Basic information

• Product Name: 3-CYCLOPROPYL-1H-PYRAZOLE
• Synonyms: AKOS B021889;3-CYCLOPROPYL-1H-PYRAZOLE;ART-CHEM-BB B021889;3-Cyclopropylpyrazole;3-Cyclopropyl-1H-pyrazole 97+%
• CAS NO: 100114-57-6
• Molecular Formula: C₆H₈N₂
• Molecular Weight: 108.14
• Mol File: 100114-57-6.mol

Chemical Properties

• Boiling Point: 112-114℃ (8 Torr)
• Flash Point: 126.9±11.7℃
• Appearance: Colorless/Liquid
• Density: 1.215±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.0158mmHg at 25°C
• Refractive Index: 1.608
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.56±0.10(Predicted)
• CAS DataBase Reference: 3-CYCLOPROPYL-1H-PYRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CYCLOPROPYL-1H-PYRAZOLE(100114-57-6)
• EPA Substance Registry System: 3-CYCLOPROPYL-1H-PYRAZOLE(100114-57-6)

Safety Data

• Hazardous Substances Data: 100114-57-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Cyclopropyl-1H-pyrazole is used as a building block for the synthesis of pharmaceuticals due to its compatibility with biological targets, such as enzymes and receptors. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Cyclopropyl-1H-pyrazole is utilized as a component in the creation of agrochemicals, contributing to the development of effective pesticides and other agricultural products that can enhance crop protection and yield.
Used in Organic Synthesis:
3-Cyclopropyl-1H-pyrazole serves as a key intermediate in organic synthesis, enabling the production of a wide range of organic compounds for various applications, including but not limited to, the synthesis of fine chemicals and specialty materials.
Used in Medicinal Chemistry Research:
As a compound with potential interactions with biological targets, 3-Cyclopropyl-1H-pyrazole is used in medicinal chemistry research to explore its properties and applications in drug discovery, potentially leading to the development of novel therapeutic agents.

InChI:InChI=1/C6H8N2/c1-2-5(1)6-3-4-7-8-6/h3-5H,1-2H2,(H,7,8)

Upstream product

• 21387-33-7 4,4',5,5'-tetrahydro-3H,3'H-3,3'-bipyrazole 
• 6746-94-7 Cyclopropylacetylene 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 765-43-5 Cyclopropyl methyl ketone 
• 21666-68-2 1-cyclopropyl-3-(dimethylamino)prop-2-en-1-one 
• 21666-68-2 (E)-1-cyclopropyl-3-(dimethylamino)prop-2-en-1-one 

Downstream Products

• 220460-88-8 [4-(3-Cyclopropyl-pyrazol-1-yl)-2-trifluoromethy-phenyl]-(5H,11H-pyrrolo[2,1-c][1,4]benzodiazepin-10-yl)-methanone 
• 1249581-67-6 3-cyclopropyl-4-nitro-1H-pyrazole 
• 957345-28-7 4-bromo-3-cyclopropyl-1H-pyrazole 
• 957292-12-5 2-(3-cyclopropyl-1H-pyrazol-1-yl)acetic acid 
• 1053163-67-9 1-methyl-3-cyclopropylpyrazole 
• 1172797-65-7 1-methyl-5-cyclopropyl-pyrazole 

Relevant articles and documents

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.

Preparation technology of 3-cyclopropyl-1-methyl-1H-pyrazole-4-formaldehyde

The invention provides a preparation technology of 3-cyclopropyl-1-methyl-1H-pyrazole-4-formaldehyde (compound 1). The preparation technology comprises the following steps: 1) 1-cyclopropyl methyl ketone reacts with N,N-dimethylformamide dimethylacetal in N,N-dimethylformamide solvent at a proper temperature to obtain a compound 2; 2) the compound 2 reacts with hydrazine hydrate react in an alcohol solvent at a reflux temperature to obtain a compound 3; 3) the compound 3 reacts with a methylation reagent at room temperature to obtain a compound 4; 4) the compound 3 reacts with N,N-dimethylformamide in a halohydrocarbon solvent in an ice-water bath, to obtain the 3-cyclopropyl-1-methyl-1H-pyrazole-4-formaldehyde (compound 1). The synthesis route is shown in the description. According to thepreparation technology provided by the invention, the adopted raw materials, reagents and solvents are conventional synthetic reagents which are cheap and easily available; the reaction conditions inall steps are mild, the aftertreatment is simple, the reaction yield is relatively high, and the product purity is high. Overall preparation cost of the product is low, and the requirements of industrial production are met.

PYRAZOLE DERIVATIVES

Provided herein are compounds of the formula I: as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment or prevention of mGluR5 mediated disorders, such as acute and/or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain.

PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS

Compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the com

Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with new piperidine 4-alkenyl derivatives that possess unique antiviral activity. More particularly, the present invention relates to compounds useful for the treatment of HIV and AIDS. The compounds of the invention for the general Formula I: wherein: Z is Q is selected from the group consisting of: —W— is

Generation and intermolecular capture of cyclopropylacyl radicals

(Chemical Equation Presented) Cyclopropylacyl radicals derived from S-cyclopropylacyl xanthates (dithiocarbonates) undergo intermolecular additions to olefins without loss of CO or ring opening. In the presence of a phenyl ring on carbon C-1 of the cyclopropane ring, loss can be made to occur in the absence of an olefinic trap. The adducts from the cyclopropylacyl radical additions are easily converted into enones by base-induced β-elimination of the xanthate group.